Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia

Inclusion Criteria:

• Diagnosis of AML in accordance with the World Health Organization criteria.

• Ineligibility for induction chemotherapy due to age (≥ 70 years) or, for patients 18to 74 years of age, ECOG-PS 2 or 3, creatinine clearance below 60 mL/min/1,73m²,left ventricular ejection fraction ≤ 50%.

• Projected life expectancy of at least 12 weeks.

• Not requiring supplemental oxygen or substitutive renal therapy.

• Female participants must be either postmenopausal, surgically sterile or practicingat least one protocol specified method of birth control starting at Study Day 1through at least 180 days after the last dose of study drug.

• Male participants must agree, from Study Day 1 through at least 180 days after thelast dose of study drug, to practice protocol specified methods of contraception andto refrain from sperm donation from initial study drug administration through atleast 180 days after the last dose of study drug.

• Participant must voluntarily sign and date an informed consent form, approved by anIndependent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to theinitiation of any screening or study-specific procedures.

Exclusion Criteria:

• Diagnosis of acute promyelocytic leukemia (APL).

• Known central nervous system (CNS) involvement with AML.

• Known human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV), orhepatitis C virus (HCV) infection, or other active viral, bacterial or fungalinfection requiring treatment.

• History of other malignancies prior to study entry, with the exception ofnon-melanoma skin cancer.

• Chronic Liver Disease and Cirrhosis with a class B or C Child-Pugh score.